Introduction
Apoptosis, a morphologically and biochemically de®ned form of cell death (Kerr et al., 1972) , has been demonstrated to play a role in a wide variety of biological systems, including physiological cell turnover, the immune system, embryonic development, and hormone-dependent atrophy (Cohen et al., 1992; Ellis et al., 1991; Krammer et al., 1994) . Although the primary targets of chemotherapeutic antitumor agents comprise distinct intracellular structures, such as the nucleus, the cell membrane and the cytoskeleton, considerable evidence exists that drug-induced cytotoxicity leads to the activation of common apoptotic pathways (Fisher, 1994; Hannun, 1997) . However, acquired drug resistance represents a major drawback in chemotherapy and is the main reason for the failure of chemotherapy to cure cancer. Dysfunction of apoptotic pathways has been implicated in the mechanisms leading to the selection of drug resistant cell clones. For example, the deregulated expression of anti-apoptotic Bcl-2 family members can confer drug resistance in transfected tumor cells (Lotem and Sachs, 1993; Miyashita and Reed, 1993) . On the other hand, overexpression of Bax-a, a proapoptotic member of the Bcl-2 family, in breast cancer cells reversed the malignant phenotype with regard to tumorigenicity in a SCID mouse xenotransplant model and increased the sensitivity of these cells to apoptosis . In this line, we and others established that the loss of Bax expression in metastatic breast (Krajewski et al., 1995; or colorectal cancer ) is a negative prognostic factor for response to cancer therapy. Inactivation of the apoptosis machinery by loss of Bax may occur at the time of tumor relapse after chemotherapy as recently demonstrated in childhood acute lymphoblastic leukemia (Prokop et al., 2000) .
The central component of the apoptotic machinery is a proteolytic system consisting of a family of cysteinyl proteases with an absolute requirement for cleavage after aspartic acid, therefore called caspases (for reviews see Cohen, 1997; Thornberry and Lazebnik, 1998) . In mammalian cells, at least 14 dierent caspases exist. The members of the caspase family can be divided into two groups: (i) upstream initiator caspases, such as caspase-8 and caspase-9, which cleave and activate other caspases; and (ii) downstream eector caspases, such as caspase-3 and caspase-6, which cleave cellular substrates thereby disassembling cellular structures or inactivating enzymes. Caspase-3 is the most intensively studied eector caspase. It has been shown that depletion of caspase-3 by homologous recombination leads to accumulation of neuronal cells whereas other tissues were not aected (Kuida et al., 1996) . Furthermore, we provided evidence that development of therapyrefractory relapse of childhood acute lymphoblastic leukemia is accompanied by a complete loss of spontaneous processing of caspase-3 (Prokop et al., 2000) . Mutations of caspase-3 have been described in cell line models. Recently, loss of caspase-3 due to a 47-base pair deletion within exon 3 of the CASP-3 gene in the breast carcinoma cell line MCF-7 was reported leading to a blockade of DNA fragmentation in response to tumor necrosis factor (TNF) a and staurosporine (JaÈ nicke et al., 1998a) . In this line, the hierarchical activation of caspases-2, -3, -6, -7, -8 and -10 in a caspase-9 dependent manner has been shown in a cell-free system and a feedback ampli®cation loop involving caspase-3 and caspase-9 has been proposed (Slee et al., 1999) . Indeed, results from dierent laboratories con®rmed these in vitro data and evidence was provided for a caspase-3-driven ampli®cation loop during drug-induced apoptosis (Slee et al., 2000; Wieder et al., 2001 ). Thus, the intracellular level of procaspase-3 might be of importance for the impact of apoptotic stimuli. We assumed that the forced expression of this downstream apoptosis eector could not only be used to restore apoptosis sensitivity in caspase-3 de®cient MCF-7 cells but could also be employed to overcome drug resistance in breast cancer cell lines.
To investigate whether caspase-3 might revert drug resistance and in¯uence apoptotic signaling, the enzyme was stably overexpressed by retroviral gene transfer in the drug resistant breast cancer cell line, MT1/ADR, which was selected from the drugsensitive MT1 cell line by culture in the presence of doxorubicin (Stein et al., 1997) . MT1/ADR cells carry the p53 wild type gene and do not show increased drug eux, but instead display a defect in the activation of the mitochondrial apoptosis machinery which can be reverted by overexpression of Bak or Bik/Nbk (PT Daniel and S Radetzki, unpublished observation). For example, speci®c apoptosis after challenge with 2.5 mg/ml epirubicin was increased from 13.2% in pcDNA3-transfected MT1/ADR cells to 52.5% in bak-transfected cells and to 21.3% in bik/nbk-transfected cells. Additionally, these cells express low levels of functional, i.e. wild type procaspase-3.
In the present study, we demonstrate that restoration of caspase-3 expression is necessary for apoptotic DNA fragmentation when MCF-7 cells were treated with epirubicin, etoposide and taxol. In the case of MT1/ ADR cells, we show that the sensitivity against all three drugs was signi®cantly enhanced by overexpression of procaspase-3 and nearly reached the same level of sensitivity as compared with the original drug sensitive MT1 cell line. Thus, procaspase-3 could serve as a future target gene to enhance chemosensitivity even in cells with defective activation of upstream eectors of the mitochondrial apoptosome.
Results
Chemotherapeutic drugs induce apoptotic cell death in procaspase-3-transfected MCF-7 cells MCF-7 breast carcinoma cells are widely used as a model system for breast cancer. Recently, it has been demonstrated that MCF-7 cells do not express caspase-3, and MCF-7 clones stably transfected with full length procaspase-3 cDNA were generated (JaÈ nicke et al., 1998a) . To determine the role of caspase-3 in such a knock-out model, we tested caspase-3-de®cient and caspase-3-reconstituted MCF-7 cells for drug-induced apoptosis. In a ®rst set of experiments, we checked the expression of caspase-3 and caspase-3-like activity in pcDNA3-transfected and caspase-3-transfected MCF-7 cells. As shown in Figure  1a , vector-transfected MCF-7 cells did not express any immuno-detectable procaspase-3 whereas caspase-3-transfected MCF-7 cells contained signi®cant amounts of the proenzyme. Furthermore, we found only marginal caspase-3-like enzyme activity in vectortransfected MCF-7 cells below 0.1 mM/min, even when the apoptotic cascade was triggered in vitro by addition of cytochrome c/dATP as previously described in HeLa cell extracts (Liu et al., 1996) . On the other hand, basal caspase-3-like enzyme activity was 0.29 mM/min in caspase-3-transfected MCF-7 cells. This basal activity was stimulated by about 13-fold in the presence of cytochrome c/dATP (Figure 1b ) thereby indicating that the components required for activation of caspase-3 by mitochondrial release of cytochrome c are present and fully functional in MCF-7 cells.
We employed caspase-3-transfected MCF-7 cells as a positive control and compared the results with essentially caspase-3-free MCF-7 vector controls to show the eect of defective caspase-3 activation on drug-induced cell death. The nuclear alterations associated with apoptosis are characterized by internucleosomal cleavage of DNA (Wyllie, 1980) leading to the appearance of a sub G1-peak in apoptotic cells when cellular DNA is analysed by¯ow cytometry. Figure 2 shows the nuclear DNA fragmentation pro®les of mock-transfected MCF-7 cells as compared with caspase-3-transfected MCF-7 cells after treatment with dierent drugs. As expected, vector-transfected MCF-7 cells were very insensitive in response to epirubicin, etoposide and taxol and DNA fragmentation did not exceed 30%, even at high concentrations of the respective drugs (Figure 3 ). In contrast, caspase-3-transfected MCF-7 cells displayed high sensitivity towards epirubicin and etoposide and incubation with 0.3 mg/ml epirubicin or 40 mg/ml etoposide led to an accumulation of 80% apoptotic cells. Although the eect was not as dramatic as compared with the other drugs, taxol-induced apoptosis was also enhanced in caspase-3-transfected MCF-7 cells. Furthermore, we determined the cytotoxicity of all three drugs as assessed by the release of cytosolic LDH in this experimental system. However, caspase-3-transfection 6 caspase-3-transfected cells (B) were prepared and 30 mg of cellular protein were loaded per lane. Proteins were separated by SDS ± PAGE and immunoblotting using an anti-caspase-3 antibody was performed as described in Materials and methods. Positions of molecular weight standards are shown. (b) Caspase-3 activity was measured in extracts from vector-(pcDNA3) or caspase-3-transfected MCF-7 (Casp.3) cells after in vitro activation with 1 mM dATP and 10 mM cytochrome c (+). Controls were incubated in the absence of dATP and cytochrome c (7). Data are given in mM DEVD-pNA cleaved per min and represent the mean of two determinations with an error of less than 10%. The experiment was repeated and similar results were obtained Figure 2 FACS pro®les of mock-and caspase-3-transfected MCF-7 cells after epirubicin, etoposide and taxol treatment. Mocktransfected (MCF-7/pcDNA3) and procaspase-3-transfected MCF-7 cells (MCF-7/Casp.3) were treated with 1 mg/ml epirubicin, 40 mg/ml etoposide or 10 mg/ml taxol as indicated. After 72 h of incubation, DNA fragmentation was determined as described in Materials and methods. A representative FACS pro®le of each experiment is shown and cells displaying hypodiploid DNA are given in per cent of the total population in MCF-7 cells only in¯uenced the general cytotoxic eects of epirubicin, etoposide or taxol at concentrations 41 mg/ml, 410 mg/ml or 41 mg/ml, respectively, whereas at very high drug concentrations 100% of the cells died irrespective of caspase-3 transfection via necrotic cell death (Figure 3d ± f). In the case of taxol treatment, induction of necrotic cell death might explain the bell shaped dose/response curve which was observed in pcDNA-3-mock-transfected MCF-7 cells (Figure 3c ). In the mock-transfectants, taxol preferentially induces apoptosis at concentrations 40.1 mg/ml. However, the relative amount of apoptotic cells after challenge of the mock transfectants with 1 mg/ml or 10 mg/ml taxol even declines whereas the proportion of dead cells increases from 20% after treatment with 1 mg/ml taxol to 100% after treatment with 10 mg/ml taxol. The`dip' observed in the dose/ response curve for apoptosis induction in the procaspase-3-transfected MCF-7 and in the LDH measurements for both cell lines may therefore be the 
Characterization of MT1/ADR clones
Drug resistance is often correlated with dysfunction or dysregulation of apoptotic pathways and overexpression of downstream eectors, such as caspase-3, might restore or enhance chemosensitivity. To investigate this hypothesis, we used the breast carcinoma cell line MT1 (Naundorf et al., 1992) and its drug resistant counterpart MT1/ADR which was selected by treatment with increasing concentrations of doxorubicin for several weeks (Stein et al., 1997) . Interestingly, the drug resistance of MT1/ADR cells is due to a defect at the level of the mitochondrial apoptosome and transfection of proapoptotic genes, e.g. bak and nbk, restores mitochondrial activation and drug sensitivity of these cells (PT Daniel and S Radetzki, unpublished observation). Three clones of MT1/ADR cells stably expressing exogenous procaspase-3 were generated as demonstrated by vector speci®c RT ± PCR analysis ( Figure 4 ). In contrast, exogenous procaspase-3 was absent in MT1, vector-transfected MT1/ADR and untransfected MT1/ADR cells (Figure 4 ). To con®rm that expression of exogenous procaspase-3 leads to higher protein levels in positive clones, Western blot analyses and measurements of caspase-3-like enzyme activities were performed. As shown in Figure 5a , MT1 and MT1/ADR contained relatively low endogenous levels of procaspase-3. This level was not signi®cantly altered by transfection of MT1/ADR with the control vector LXSN. In contrast, the caspase-3-transfected MT1/ADR clones 11, 12 and 14 contained signi®cantly higher procaspase-3 levels. Quantitation of the procaspase-3 band by videodensitometry revealed a 2.8+0.3-fold increase in caspase-3-transfected MT1/ADR cells as compared with the parental MT1/ADR cell line (Figure 5b ). Overexpression of procaspase-3 protein was not accompanied by spontaneous caspase-3 activation and we could not detect mature p17 subunits in the procaspase-3-transfected clones ( Figure 5a ). As a consequence, the stable overexpression of procaspase-3 alone induced neither apoptosis-like cell death nor morphological changes (data not shown) thereby con®rming similar observations in NIH3T3 cells using procaspase-1 (Hiwasa et al., 1998 ). Nevertheless, we tested whether the higher levels of procaspase-3 in positive clones could be in vitro activated by addition of 1 mM dATP and 10 mM cytochrome c thus resulting in higher speci®c enzyme activities. In accordance with the absence of mature p17 subunits of caspase-3 under control conditions, neither caspase-3-nor LXSNmock-transfected MT1/ADR cells contained signi®cant amounts of caspase-3-like activity when assayed in caspase-3-transfected (MT1/ADR/C3, clones 11, 12 and 14) and 2610 6 mock-transfected cells (MT1/ ADR/LXSN, clones 9 and 10) were prepared. In addition, extracts from 2610 6 untransfected MT1 and 2610 6 MT1/ADR cells were included. Thirty mg of cellular protein were loaded per lane, proteins were separated by SDS ± PAGE and immunoblotting using anti-caspase-3 antibody was performed as described in Materials and methods. Positions of molecular weight standards are shown. (b) The expression of procaspase-3 was quanti®ed by videodensitometry using a Gel Doc 2000 apparatus (Biorad; MuÈ nchen, Germany) and optical density of the procaspase-3 band is given in arbitrary units. The experiment was repeated and similar results were obtained extracts which had not been in vitro activated (data not shown). On the other hand, caspase-3-like enzyme activity after in vitro activation was signi®cantly increased in caspase-3-transfected MT1/ADR clones ( Figure 6 ). As compared with untransfected MT1/ ADR cells this increase reached 3.7+0.7-fold. In LXSN-mock-transfected MT1/ADR cells, enzyme activity was slightly higher as compared with untransfected MT1/ADR cells (Figure 6 ). This increase, however, was not signi®cant. Thus, expression levels of procaspase-3 nicely correspond to the inducible caspase-3-like activity in a cell-free system.
Enhancement of apoptotic DNA fragmentation by different cytotoxic drugs in procaspase-3-transfected MT1/ADR cells As demonstrated in MCF-7 cells, caspase-3 is necessary for drug-induced DNA fragmentation and apoptotic cell death. We now asked whether overexpression of procaspase-3 might sensitize the drug-resistant breast cancer cell line MT1/ADR for drug-induced apoptosis and thereby overcomes drug resistance in this cell line model. Figure 7 shows the apoptosis induction of mock-transfected MT1/ADR cells or caspase-3-transfected MT1/ADR cells after treatment with dierent drugs as determined by analysis of nuclear DNA fragmentation by¯ow cytometry on the single cell level. As expected, MT1/ADR cells were very insensitive to treatment with epirubicin, etoposide and taxol (Figure 8 ). Apoptotic cells were below 25% even when the cells were treated with 10 mg/ml epirubicin ( Figure  8a ), 80 mg/ml etoposide (Figure 8b ) or 0.8 mg/ml taxol (Figure 8c ). In contrast, the original cell line MT1 already showed induction of apoptosis in the presence of lower drug concentrations and in all cases the number of cells with hypoploid DNA reached 75% (Figure 8d ± f) . When caspase-3-transfected MT1/ADR cells were treated with dierent concentrations of epirubicin (Figure 8a ), etoposide (Figure 8b ) or taxol (Figure 8c ), DNA fragmentation was enhanced by at least twofold as compared with the respective vectortransfected control cells. Apoptosis nearly reached the same levels as in the original MT1 cell line indicating that overexpression of procaspase-3 in MT1/ADR cells leads to ampli®cation of drug-induced apoptotic pathways culminating in internucleosomal breakdown of DNA. Interestingly, we could demonstrate that the stable transfection of procaspase-3 did not in¯uence cells with intact apoptotic signaling. For this, we generated stable clones of drug-sensitive MT1 cells overexpressing procaspase-3. These cells showed a 4.5+0.6-fold increase of procaspase-3 as compared with the parental MT1 cell line (Figure 9) . Thus, the overexpression of procaspase-3 was in the same range as described for the drug-resistant MT1/ADR cells. In contrast to drug-resistant MT1/ADR cells, overexpression of procaspase-3 in drug-sensitive MT1 cells did not further sensitize the cells for epirubicin-induced apoptosis (Figure 9c ). Similar results were obtained using etoposide or taxol and a sensitizing eect of procaspase-3 was not observed in MT1 cells (data not shown).
Discussion
Drug resistance is one of the major draw backs of chemotherapy and new therapeutical strategies to overcome this problem are necessary. Several anticancer drugs have been demonstrated to induce apoptotic cell death and to activate caspases in a variety of cellular systems (Essmann et al., 2000; Ibrado et al., 1996a,b; Suzuki et al., 1998; Wesselborg et al., 1999) . Although these cytotoxic agents head for dierent primary targets it has become obvious that in most cases drug-induced apoptosis converges on a common pathway, causing mitochondrial membrane permeabilization (Kroemer and Reed, 2000) and subsequent activation of downstream caspases, such as caspase-3. Dysfunction of apoptotic pathways has been implicated in the development of drug resistance. In this line, we recently demonstrated that therapyrefractory relapse of childhood acute lymphoblastic leukemia is accompanied by a drastic decline of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 Figure 6 Determination of caspase-3-activity in MT1/ADR. Caspase-3 activity was measured in extracts from procaspase-3-transfected (MT1/ADR/C3, clones 11, 12, and 14) or mocktransfected cells (MT1/ADR/LXSN, clones 9 and 10) and in extracts from untransfected MT1 or MT1/ADR cells after in vitro activation with 1 mM dATP and 10 mM cytochrome c as described in Materials and methods. Data are given in mM DEVD-pNA cleaved per (min6mg cellular protein)+s.d. (n=3). **Signi®-cantly dierent from MT1/ADR cells at P50.01, ***Signi®cantly dierent from MT1/ADR cells at P50.001 processing in vivo (Prokop et al., 2000) . In the same context, we have previously shown that overexpression of proapoptotic regulators, such as Bax Wagener et al., 1996) or Bik/Nbk , increases the sensitivity of cancer cell lines for drug-induced apoptosis. However, Bcl-2 type regulators of apoptosis pathways are located upstream of the mitochondrion which represents a central checkpoint of these pathways.
In the present study, we asked whether gene transfer of the downstream eector procaspase-3 would also lead to sensitization of drug-resistant cancer cells. As model systems we used the caspase-3-de®cient breast cancer cell line MCF-7 (JaÈ nicke et al., 1998a) and drug-resistant MT1/ADR cells (Naundorf et al., 1992; Stein et al., 1997) which show a defect in the formation of the mitochondrial deathinducing signaling complex and impaired activation of caspase-3 (PT Daniel and S Radetzki, unpublished observation). In a ®rst set of experiments, we could clearly demonstrate that only MCF-7 cells which had been transfected with procaspase-3 underwent apoptosis after challenge with dierent chemotherapeutics. Caspase-3 is therefore necessary for epirubicin-, etoposide-and taxol-induced apoptosis, at least in this particular caspase-3 knock-out model system. Our results are consistent with previous reports showing that caspase-3 is indispensable for DNA fragmentation and a-fodrin cleavage after TNF a-and staurosporine-treatment but not for cell death in general (JaÈ nicke et al., 1998a,b).
In a second experimental model, we investigated the breast cancer cell line MT1 and its drug resistant counterpart MT1/ADR. We generated dierent MT1/ ADR clones carrying exogenous procaspase-3 by retroviral transfer of the procaspase-3 gene into MT1/ADR cells. Stable transfection of the procaspase-3 gene led to moderate but signi®cantly higher expression of the proenzyme. The very similar and rather low levels of procaspase-3 in the MT1/ADR/C3 clones analysed in our study can be explained by the assumption that cells with higher levels of procaspase-3 have been eliminated during the selection of the clones. However, stable transfection of procaspase-3 did not aect background apoptosis levels of the cells (see Figure 8 ). This diers from the results of previous studies which used the proapoptotic proteins Bax or apoptotic protease activating factor-1 (Apaf-1). It was shown that controlled expression of Bax, without another death stimulus, is sucient to induce apoptosis in Jurkat cells (Xiang et al., 1996) . In the case of Apaf-1, overexpression of this adaptor molecule not only sensitized HL-60 cells to taxol-and etoposide-induced apoptosis but also signi®cantly increased background apoptosis in transfected cells (Perkins et al., 1998) . All the more, our procaspase-3-overexpressing MT1/ADR clones represent an interesting cellular system to investigate whether enforced expression of this downstream eector might overcome drug resistance. We could demonstrate that MT1/ADR cells stably transfected with procaspase-3 were signi®cantly more susceptible to treatment with epirubicin, etoposide and taxol as compared with the mock-transfected MT1/ADR cells. The enhanced susceptibility of procaspase-3 overexpressing cells can be explained by the ®ndings that caspase-3 is involved in dierent ampli®cation loops thereby multiplying the impact of a given death stimulus. For example, it has been shown that drug treatment triggers caspase-3-mediated cleavage of Bid. Truncated Bid then enhances the apoptotic signal upstream of mitochondria (Slee et al., 2000) . Furthermore, as evidenced recently, the molecular order of drug-induced apoptosis in B lymphoid cells is represented by the Fas/CD95-independent, hierarchical activation of mitochondrial cytochrome c release, caspase-3 and caspase-8 (Wieder et al., 2001) . In this system, caspase-8 functions as an ampli®er and not as an initiator caspase.
As already mentioned above, caspase-3-transfected MT1/ADR cells were more sensitive to cytotoxic drugs as compared with vector-transfected controls and DNA fragmentation nearly reached the levels of the original drug sensitive MT1 cells. Interestingly, the drug resistance of MT1/ADR cells is due to a defect at the level of the mitochondrial apoptosome. Theoretically, transfection of caspase-3 should therefore have no eect since activation of the mitochondrial apoptosome is the dominant signaling pathway for drug-induced apoptosis (Kroemer and Reed, 2000) and caspase-3 activation is presumed to occur downstream of caspase-9 activation. In our system, however, caspase-3 overexpression appears to bypass this eect since the Figure 8 Induction of apoptosis by epirubicin, etoposide and taxol in mock-and procaspase-3-transfected MT1/ADR cells. Clones 9, 10 and 11 of mock-transfected (*) or clones 11, 12 and 14 of procaspase-3-transfected MT1/ADR cells (*) were treated with dierent concentrations of epirubicin (a), etoposide (b) or taxol (c). Additionally, MT1/ADR (*) or MT1 cells (*) were treated with dierent concentrations of epirubicin (d), etoposide (e) or taxol (f). After 72 h of incubation, DNA fragmentation was determined as described in Materials and methods. Data are given as per cent hypoploidy and represent the mean of three independent experiments+s.d.
Caspase-3 gene transfer and chemoresistance K Friedrich et al MT1/ADR cells, which are defective at the level of cytochrome c release and mitochondrial permeability shift transition, were sensitized for apoptotic cell death upon transduction of the caspase-3 construct. This, in turn, suggests that activation of caspase-3 in MT1/ ADR cells may even occur in the presence of mitochondrial signaling defects.
From our results, we conclude that enhanced expression of the central executioner of apoptotic pathways, caspase-3, in the form of its inactive proenzyme can overcome acquired drug resistance. Thus, caspase-3 could serve as a target gene to enhance chemosensitivity not only by gene transfer but also by new drugs even in situations where the activation of the mitochondrial apoptosome is defective, e.g. as consequence of a loss of Bax or overexpression of Bcl-2 which are both frequently observed in breast cancer and other tumors (Bargou et al., 1995; Sturm et al., 1999 Sturm et al., , 2000 Prokop et al., 2000) .
Materials and methods

Materials
Polyclonal rabbit anti-human caspase-3 antibody (developed against human recombinant protein and recognizing unprocessed procaspase-3 and the 17 kDa subunit of active caspase-3) was from PharMingen (Hamburg, Germany) and used at a dilution of 1 : 1000. Secondary anti-rabbit, horse radish peroxidase conjugated antibody was from Promega (Mannheim, Germany). Caspase-3 substrate (Ac-DEVD-pNA) was from Calbiochem-Novabiochem GmbH (Bad Soden, Germany). RNase A was from Roth (Karlsruhe, Germany). Epirubicin was purchased from Pharmacia Upjohn (Erlangen, Figure 9 Overexpression of procaspase-3 in MT1 and induction of apoptosis by epirubicin. (a) Extracts from each 2610 6 procaspase-3-transfected (MT1/C3), mock-transfected (MT1/LXSN) and untransfected MT1 cells (MT1) were prepared. Thirty mg protein were loaded per lane, proteins were separated by SDS ± PAGE and immunoblotting using anti-caspase-3 antibody was performed as described in Materials and methods. (b) The expression of procaspase-3 was quanti®ed by videodensitometry and optical density of the procaspase-3 band is given in arbitrary units. (c) MT1/LXSN (*) or MT1/C3 cells (*) were treated with dierent concentrations of epirubicin as indicated in the ®gure. After 72 h, DNA fragmentation was determined. The data of a representative experiment are given in per cent hypoploidy. Data points represent the mean of two determinations with an error of less than 10%. The experiment was repeated and similar results were obtained Germany), etoposide and taxol (paclitaxel) were from Bristol Arzneimittel GmbH (MuÈ nchen, Germany).
Cell culture
Control vector (pcDNA3-transfected) and pcDNA3-caspase-3-transfected MCF-7 cells (JaÈ nicke et al., 1998a) were grown in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal calf serum (FCS), 0.56 g/l Lglutamine, 100 000 international units (IU)/penicillin and 0.1 g/l streptomycin. Media and culture reagents were from Life Technologies GmbH (Karlsruhe, Germany). Con¯uent cells were subcultured every 5 days after detaching the cells with a Trypsin/EDTA solution (Sigma; MuÈ nchen, Germany).
Vector construction and transfection of packaging cells
The caspase-3 cDNA was ampli®ed by polymerase chain reaction (PCR) from human cDNA using the following primers: sense: 5'-AAC GAA TTC CCA CCA TGG AGA ACA CTG AAA ACT CAG-3' antisense: 5'-AAC GAA TTC TTA GTG ATA AAA ATA GAG TTC-3'. The resulting product was digested with EcoRI and the 847 bp caspase-3 fragment was cloned nondirectedly into the corresponding sites of retroviral vector pLXSN (Miller and Rosman, 1989) which was kindly provided by T Blankenstein (Max DelbruÈ ck Centrum; Berlin, Germany). The orientation of the caspase-3 fragment was tested by HindIII digestion and sequence analysis of the caspase-3/pLXSN construct was performed on a ABI PRISM 310 Genetic Analyzer (Applied Biosystems; Weiterstadt, Germany) using a standard protocol.
The amphotropic packaging cell line FlyA (Cosset et al., 1995) was transfected with the caspase3/pLXSN-expression construct (7.5 mg and 15 mg) by Ca 3 (PO 4 ) 2 precipitation using the Mammalian Transfection Kit (Stratagene; Heidelberg, Germany) according to the manufacturer's instructions. Stable virus-producing transfectants were selected using 1 mg/ml geneticin 418 (G418) (Gibco ± BRL; Karlsruhe, Germany) and maintained in DulbeccoÂ s minimal essential medium (DMEM) supplemented with 10% heat-inactivated FCS, 0.56 g/l L-glutamine, 100 000 IU/penicillin and 0.1 g/l streptomycin. All products were purchased from Gibco ± BRL. The colonies were expanded for analysis and virusproduction. Control transfectants carrying the pLXSN-vector alone were generated and selected in parallel.
Reverse transcription and PCR ampli®cation for testing virus-producing transfectants were performed as described . The following primers were used for ampli®cation: sense: 5'-CCG GAA TTC CCA CCA TG-3' antisense: 5'-AAC GAA TTC TTA GTG ATA AAA ATA GAG TTC-3'. PCR products were separated on 1% agarose gel and DNA was visualized by ethidiumbromide staining.
Virus titration
The titers of the virus-containing supernatants of positive clones were determined on D17 cells (Uckert et al., 1998) . Cells were grown in a-MEM (Gibco ± BRL) and infected using dierent virus concentrations in the presence of 8 mg/ml polybrene. After selection using 0.8 mg/ml G418, colonies were counted.
Infection of target cell lines
MT1 and MT1/ADR mammary carcinoma cells (Naundorf et al., 1992; Stein et al., 1997) were cultured in RPMI 1640 supplemented with 10% heat-inactivated FCS, 0.56 g/l Lglutamine, 100 000 IU/penicillin and 0.1 g/l streptomycin (Gibco ± BRL). Cells were infected three times with 2 ml caspase-3 virus-containing supernatant (at 10 6 plaque forming units (p.f.u.)/ml) or pLXSN control virus-containing supernatant (mock) in the presence of 8 mg/ml polybrene and then selected in medium containing 1 mg/ml G418. The colonies were expanded for analysis and the supernatants were found to be free of replication-competent viruses.
Transgene detection by PCR
Stable transfectants were tested for expression of the transgene by reverse transcription and PCR ampli®cation as described using the following primers containing sequences of caspase-3 as well as sequences of the LXSN-vector: sense: 5'-CCG GAA TTC CCA CCA TG-3' antisense: 5'-TTG TGA GCA TGG AAA CAA TAC-3'. The PCR products were separated on 1% agarose gel and the DNA was visualized by ethidiumbromide staining.
Measurement of cell death
Cytotoxicity of the dierent drugs was measured by the release of lactate dehydrogenase (LDH) as described previously (Wieder et al., 1998) . After incubation with dierent concentrations of epirubicin, etoposide or taxol, LDH activity released by the cells was measured in the cell culture supernatants using the Cytotoxicity Detection Kit from Boehringer-Mannheim (Mannheim, Germany). The supernatants were centrifuged at 300 g for 5 min. Twenty ml of cell-free supernatants were diluted with 80 ml phosphate buered saline (PBS) and 100 ml reaction mixture containing 2-[4-Iodophenyl]-3-[4-nitrophenyl]-5-phenyltetrazolium chloride (INT), sodium lactate, NAD + and diaphorase were added. Then, time-dependent formation of the reaction product was quanti®ed photometrically at 490 nm. The maximum amount of LDH activity released by the cells was determined by lysis of the cells using 0.1% Triton X-100 in culture medium and set as 100% cell death.
Measurement of apoptotic cell death by flow cytometry
Apoptosis was determined on a single cell level by measuring the DNA content of individual cells on a Fluorescence activated cell (FAC)Scan (Becton Dickinson; Heidelberg, Germany) as described with some modi®cations (Nicoletti et al., 1991) . After incubation of the cells with dierent concentrations of epirubicin, etoposide or taxol, cells were ®xed with 2% formaldehyde in PBS for 30 min on ice. Thereafter, cells were spun down at 300 g for 3 min. Supernatants were removed and cell pellets were resuspended by vortexing. Fifty ml PBS and 100 ml ice-cold ethanol were added and incubated for 15 min on ice. After centrifugation at 300 g for 3 min, supernatants were removed and 50 ml DNase-free RNase (40 mg/ml) from Boehringer Mannheim were added and incubated for 30 min at 378C. After washing with PBS, 200 ml propidium iodide solution (50 mg/ml in PBS) were added to the resuspended cell pellets. Cellular DNA content was measured with logarithmic ampli®cation in the FL-3 channel of the FACScan. Single cells were identi®ed and gated by pulse code processing of the area and width of the signal. Cell debris was excluded by appropriately raising the forward scatter threshold. Apoptotic nuclei display a decreased DNA content below the G1 peak paralleled by an increase of the side scatter. Data are given in per cent hypoploidy, i.e. the percentage of nuclei sub G1, which re¯ects the number of apoptotic cells.
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Immunodetection of caspase-3 protein in stable clones
Cells in log phase were harvested, washed twice with PBS and lysed in buer L (10 mM Tris/HCl, pH 7.5, 300 mM NaCl, 1% Triton X-100, 2 mM MgCl 2 , 5 mM ethylenediamine tetraacetic acid (EDTA), 1 mM pepstatin, 1 mM leupeptin, 0.1 mM phenylmethylsulfonyl¯uoride (PMSF)). Protein concentration was determined using the bicinchoninic acid (BCA) assay (Smith et al., 1985) from Pierce (Rockford, IL, USA) and equal amounts of protein (20 mg per lane) were separated by sodium dodecylsulphate (SDS)-polyacrylamide gel electrophoresis (Laemmli, 1970) . Then, immunoblotting was performed essentially as described (Wieder et al., 1994) . Membranes (Schleicher & Schuell; Dassel, Germany) were swollen in 3-[Cyclohexylamino]-1-propanesulfonic acid (CAPS)-buer (10 mM CAPS, pH 11, 10% MeOH) for several minutes and blotting was performed at 1 mA/cm 2 for 1 h in a transblot SD cell (BioRad; MuÈ nchen, Germany). The membrane was blocked for 1 h in blocking buer (16PBS, 0.05% Tween-20, 3% non fat dry milk) and incubated with polyclonal rabbit anti-human caspase-3 antibody in blocking buer for 1 h. After washing the membrane three times in PBST (16 PBS, 0.05% Tween-20) secondary antibody in PBST was applied for 1 h. Finally, the membrane was washed in PBST again and bands were detected using the enhanced chemiluminescence system (Amersham Buchler; Braunschweig, Germany) according to the manufacturer's protocol.
Measurement of caspase-3-like activity
Caspase-3 activity was measured as described (Zhou et al., 1997) with some modi®cations. Cells were washed twice with PBS and carefully collected in PBS by use of a cell scraper (Costar; Cambridge, MA, USA). Cells were spun down at 200 g, 48C for 5 min and cell pellets were resuspended in buer A containing 20 mM N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] (HEPES), pH 7.4, 10 mM KCl, 2 mM MgCl 2 , 1 mM EDTA, 1 mM dithiothreitol (DTT) and incubated on ice for 15 min. Cell extracts were prepared by homogenizing cells through a 21 G61 1/2 needle (Braun; Melsungen, Germany). The homogenates were cleared by centrifugation at 16 000 g, 48C for 15 min. The centrifugation step was repeated and the clear supernatants were used for the caspase assay. After determination of the protein concentration using BCA, caspase-3 activity was measured by mixing 10 ml of extract, 90 ml of buer B containing 50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 10% saccharose, 5 mM DTT, and 2 ml colorimetric substrate (10 mM Ac-DEVD-pNA in dimethylsulfoxide). Samples were incubated at 378C and the absorbance at 405 nm was measured in a microplate reader every 10 min. From the data, speci®c caspase-3 activities were calculated in mmol Ac-DEVD-pNA cleaved per (min6mg protein). Additionally, cellular extracts were preincubated with 1 mM dATP and 10 mM cytochrome c for 1 h at 308C to fully in vitro activate procaspase-3 prior to measurement of the enzyme activity.
Other procedures
Statistical comparisons were made in these studies by the use of Student's t-test.
